S. 1067 118th Congress
Ensuring Timely Access to Generics Act of 2023
Latest action, Jun 22, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 107.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
5 cosponsors
Sponsored by Jeanne Shaheen (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
2 D · 3 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
7 reports
7 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
7 reports
BCBSM INC
6 reports
6 reports
6 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
5 reports
All 25 of 26 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 8 | $15.7M | Q1 2023 | Q3 2024 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 7 | $123.5M | Q4 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.2M | Q4 2023 | Q3 2024 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 7 | $4.4M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $28.0M | Q1 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $50.1M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| TEVA PHARMACEUTICALS USA INC | 7 | $4.1M | Q4 2023 | Q3 2024 | yes | |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 7 | $380K | Q4 2023 | Q3 2024 | yes |
| BCBSM INC | 6 | $176K | Q4 2023 | Q3 2024 | yes | |
| CAMBIA HEALTH SOLUTIONS | 6 | $3.7M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 6 | $393K | Q4 2023 | Q3 2024 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 5 | $120K | Q4 2023 | Q3 2024 | yes |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 4 | $7.0M | Q2 2023 | Q4 2024 | yes | |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 3 | $500K | Q2 2023 | Q4 2024 | yes | |
| BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 3 | $25K | Q2 2023 | Q4 2024 | yes | |
| BLUE CROSS BLUE SHIELD OF MICHIGAN | 3 | $807K | Q2 2023 | Q4 2024 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING | MCDERMOTT+ LLC | 3 | $90K | Q4 2023 | Q3 2023 | yes |
| GUIDEWELL MUTUAL HOLDING CORPORATION | 3 | $10K | Q2 2023 | Q4 2024 | yes | |
| NEW VENTURE FUND | PORT SIDE STRATEGIES, LLC | 2 | $0 | Q4 2023 | Q2 2023 | yes |
| PUBLIC CITIZEN | 2 | $141K | Q4 2023 | Q2 2023 | yes | |
| ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) | FIERCE GOVERNMENT RELATIONS | 1 | $50K | Q2 2023 | Q2 2023 | yes |
| BIOGEN | 1 | $830K | Q2 2023 | Q2 2023 | yes | |
| CENTER FOR HEALTH AND DEMOCRACY | PORT SIDE STRATEGIES, LLC | 1 | $20K | Q4 2023 | Q4 2023 | yes |
| NOVARTIS | 1 | $1.4M | Q3 2023 | Q3 2023 | yes |